Startups
At this time, LUCA’s pipeline includes therapies for UTI, preterm birth and bacterial vaginosis.
This week has marked a number of stories over construction projects and real estate developers focused on the life sciences market. Here’s a look.
Since its launch, Kronos has demonstrated SMM’s potential to identify compounds that bind to target proteins directly or interfere at nanomolar potency with protein activity.
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
Arie Belldegrun, founder and former chair, president and chief executive officer of Kite Pharma, has teamed up with real estate developer Tishman Speyer to launch a biotech-focused real estate company, Breakthrough Properties.
MIT’s Research Enterprise in Singapore, SMART, launches a new research group, Critical Analytics for Manufacturing Personalized-Medicine (CAMP), as part of Singapore’s National Cell Manufacturing Initiative to overcome scientific and technical challenges in life-changing cell therapies.
Clover Therapeutics, which sprung out of Clover Health, is supported by a number of biotech and pharma veterans, including Pfizer veteran Cheng Zhang, who is heading up therapeutics, and Genentech veteran Marcel van der Brug, who is the chief scientific officer for therapeutics.
Simbec-Orion, Europe’s leading full-service boutique CRO, announces its new unified brand offering comprising the divisions previously known as Simbec Research, Orion Clinical, Orion Santé and Seirian Laboratories.
Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers.
Biotech and pharma companies strengthen their executive leadership and board positions.
PRESS RELEASES